PROBLEMS W/ (fake) NEWS ARTICLE MINYANVILLE (Trtc Ceo + Cfo 2.3 mil dump shares):
Minyanville picked up this article from ScutiFY written by this Mark Maulden. Although Minyanville has a disclaimer, however, the writer didn't have a "DISCLOSURE" and that's a first red flag. This Mark Maulden name is a somewhat common name and pretty much it could be anyone (or stolen to cover-up). In other words, there is No Background Info About the Writer -thus- No Credibility. "Mark Maulden @GanjaGuru" or @GanjaGuru in a search engine result there is really nothing. All you see is Mark Mauldinno from ScutiFY with no background, no nothing and this Nick C. (nothing to do w/ trading), but this Mark Maulden is a big fan of Canadian Cannabis Stock in Particularly $Twmjf, $Aphqf, and $Ogrmf. In the past history, he was big on $Gwph too (Jimmy aka Bigfoot was the same for these stocks). The article itself is troubling because it didn't take into consideration and left-out other information like those "recent SEC 8-K Forms", but basically it was written out of emotion, opinion, and desperation. I mean a university professor would have laughed at you for using this article as a reference in an essay. Although we do have many questions as of recent the bottom-line THAT ARTICLE IS FAKE NEWS & GARBAGE BECAUSE IT'S UNCREDIBLE like Justin. And we know this is not the 1st time it happened. LMAO!
Who says GWPH isn't poised for potentially massive upward movement? Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awe-some*sto-cks.
Gwph has the most cash. biggest mkt cap, and best potential even if mmj doesn't legalize.The drugs have to get approved and they have to be effective!
37-Year Old Diabetes Discovery Set To Launch Tiny Marijuana Biotech Stock? | The Seed Investor
This tiny Canadian biotech stock with an innovative approach may just be set up to play a major role in the the medical marijuana boom.
Yesterday's $6+ swing big even for this stock. That ended in a big drop but not to worry. You still have time to sell for over $100. Soon to be much lower with approvals AND NO USA SALES!
MICROCAP SPECIAL ALERT – BioLargo’s (BLGO) Surprise Acquisition of ENTIRE World Class Engineering Team from Fortune 500 CB&I Environmental & Infrastructure, Inc. Combined with New Financing Signals STRONG BUY as AOS Disruptive Water Treatment System Now Ready for $860 Billion Market
BLGO COMMERCIAL REVENUES ARE STARTING NOW AND STRONGLY POSITIONED TO EXPLODE FOR YEARS TO COME
Follow this chain of facts to understand the powerful investment implications:
1. BLGO developed and owns the breakthrough AOS Water Treatment system that was just unveiled at the University of Alberta. The AOS is validated by many leading experts as the biggest breakthrough in water treatment in history
2. The AOS system was validated by 1,600 studies and by the world’s largest water engineering company to disinfect and to also remove toxic contaminants better, faster and cheaper than all technologies
3. Over 35 government grants support the AOS system
4. After 10 years of development, the AOS system is now commercially ready for engineering to tailor and build it for user’s specific needs
5. BLGO just acquired THE ENTIRE ENGINEERING INNOVATION TEAM THAT CREATED GIANT REVENUES FOR CB&I and now creates instant big revenues for BLGO
6. The new engineering team brings substantial new business on day 1
7. BLGO’S new Engineering and Science Division has powerful established business relationships with giant users for the AOS
8. BLGO’s new Engineering & Science Division from CB&I is strongly incentivized to generate big and profitable revenues
9. BLGO hired Dr Shan Yong as head of BD for the AOS. Dr Yong has long established relationships with Veolia and the world’s largest water companies
10. BLGO just closed a finance commitment for $10 million with Lincoln Park Capital
11. BLGO Clyra Medical division within days of filing 510k for novel low cost, best in class wound care products in a $10 billion market
12. Clyra wound care products kill even resistant microbials (ESKAPE PATHOGENS) and promote healing
13. 510k is a 90-day process
14. Tanya Rhodes was head of wound care product development at giant Smith & Nephew
15. Tanya Rhodes is now spearheading Clyra’s disruptive product entry into $10 billion market
16. Several more proprietary blockbuster and disruptive wound care products are in pipeline
17. CupriDyne industrial air treatment odor control is being sold now and is quickly being adopted by major companies
18. 3 of the top 10 waste management companies have already signed National Purchasing Agreements and sales are increasing rapidly
19. Word on the street is that CupiDyne is going to take over odor control
20. CupriDyne sales potential is billions per year
21. BLGO is destined to achieve enormous revenues and multi-billion dollar market cap in near term with major prolonged growth for years to come.
BioLargo Acquires World-Class Engineering Team to Form a New Engineering Services Subsidiary and Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital
Westminster, CA, Sept. 11, 2017-- BioLargo, Inc., a sustainable science and technology company that delivers practical solutions for clean water, clean air and advanced wound care, announced today it finalized ...
On a day like today, this is a very impressive performance. Someone knows something imminent is about to happen...
the stock amazes me how much it bounced around I file will I do not own it
In the short-term GWPH does not seem to be like a good trade. awe-some*sto-cks alerted a new stock just now. going to check it out.
Anyone aware of a possible buyout of GWPH?
$$$$$$$$$$$$$$ N T E C $$$$$$$$$$$$$$$$$
Anyone interested in GWPH needs to read Nic Quigley's article in Seeking Alpha...
GW Pharma, the company that is growing medicinal marijuana at the former tomato glasshouses ofCornerways Nursery, has plans to gear up its plant growing and processing operations over the next.....
SLNO (MC $16 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA
Soleno therapeutics (SLNO)
Market Cap $16 Million Cash: $8 Million Price $0.35
Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
Presupposing no buy out or dilution, this co. will have a market cap of 30b$ in the near future and 100b$ in 5-7 years. Share value in the k's